Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhong Yuan Bio-Technology Holdings's earnings before interest and taxes (EBIT) for the
six
months ended in Mar. 2024 was $-0.13 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.35 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Zhong Yuan Bio-Technology Holdings's annualizedROC % for the quarter that ended in Mar. 2024 was -10.76%.
Zhong Yuan Bio-Technology Holdings's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -19.16%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhong Yuan Bio-Technology Holdings EBIT Related Terms
Zhong Yuan Bio-Technology Holdings EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Zhong Yuan Bio-Technology Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhong Yuan Bio-Technology Holdings EV-to-EBIT vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Zhong Yuan Bio-Technology Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Zhong Yuan Bio-Technology Holdings's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhong Yuan Bio-Technology Holdings (ZHYBF) has a EBIT of $0.35 Mil as of Mar. 2024. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zhong Yuan Bio-Technology Holdings.
Is Zhong Yuan Bio-Technology Holdings' EBIT too high?
Zhong Yuan Bio-Technology Holdings' current EBIT is $0.35 Mil. Overall, Zhong Yuan Bio-Technology Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Zhong Yuan Bio-Technology Holdings' EBIT compare to CLNN and JVA?
Zhong Yuan Bio-Technology Holdings' EBIT of $0.35 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Consumer Packaged Goods company?
A good EBIT depends on the Consumer Packaged Goods industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zhong Yuan Bio-Technology Holdings. Zhong Yuan Bio-Technology Holdings's current EBIT is $0.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhong Yuan Bio-Technology Holdings stock overvalued right now?
Zhong Yuan Bio-Technology Holdings (ZHYBF) has a current EBIT of $0.35 Mil. The current EBIT is $0.35 Mil. Zhong Yuan Bio-Technology Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Zhong Yuan Bio-Technology Holdings (ZHYBF), the current EBIT is $0.35 Mil as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zhong Yuan Bio-Technology Holdings Ltd is engaged in the business of developing and marketing nervonic acid-based health supplements and sales of acer truncatum seedlings. The company has two reportable segments such as sales of health care supplements and technical supporting services. The company generates its revenue primarily from the sales of health care supplements.
12GF Score
Get the complete analysis for ZHYBF
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZHYBF has been successfully added to your 
